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Abstract 
Tuberculosis (TB), a leading cause of death worldwide, in association with HIV-AIDS and the emergence of multi-drug 
resistance (MDR) or extensively drug resistance (XDR) strains, has created necessity to develop new class of anti-tubercular 
drug. Strategic implementation of hybrid computational simulation and searching method has been used to analyze and explore 
new chemical entity effective against MDR Tuberculosis strains. Initially a ligand-based pharmacophore hypothesis and 3D 
Quantitative structure activity relationship (QSAR) model with statistical significance (R2=0.985, SD=0.146, Pearson R=0.936, 
Q2= 0.849, R2Pred=0.851, Q2 (F2) =0.854) was generated by well validated algorithm. Concurrently molecular docking analysis was 
performed by considering three individual grid points of InhA enzyme. Moreover Ligand-based pharmacophoric model was 
drastically re-assessed against receptor-based docking simulation model to authenticate this in silico trialing. The docking 
analysis indicates that this class of ligands nicely occupies the hydrophobic pocket of InhA enzyme, which is an important 
feature of direct InhA inhibitors and it reveals that the chemical entities can inhibit the aforementioned enzyme without 
activating katG (a catalase/peroxidase enzyme) enzyme pathway. 
© 2013 The Authors. Published by Elsevier Ltd. 
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1. Introduction 
Mycobacterium tuberculosis, a single infectious agent causing Tuberculosis(TB)  that kills more than three million 
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people worldwide every year and every third individual of world has been exposed to or infected to M. tuberculosis 
[1,2,3]. The global incidence rate of TB is growing at 1.1% per year and the number of cases at 2.4% per year 
[1].The high susceptibility of HIV-AIDS infected people to this disease and co-infection of two pathogens is 
accelerating the collapse of immune system [2, 4]. About 3.7 million of new TB patient have multi drug resistant 
strains (MDR-TB), defined as resistant to at least Isoniazid (INH) and Rifampicin [5]. WHO has estimated that there 
are about 0.5 million cases of MDR TB and among this about 9% is extensively drug resistant strains(XDR TB), 
strains that are resistant to Isoniazid and Rifampicin , as well as any fluoro-quinolone and at least one of three 
injectable second-line drugs, such as Amikacin, Kanamycin, or Capreomycin [5]. So these clinical outcomes 
underline the need of new therapeutic entities with different mechanism of action to subside the situation.  
 
Enoyl-ACP reductase (InhA) of M. tuberculosis , participate in the Fatty acid biosynthesis pathway (FAS II) by 
utilizing NADH to reduce the trans double bond  of longer chain fatty acyl substrates for the purpose of synthesizing 
Mycolic acid ,an important factor for mycobacterium virulence [46] . InhA has been identified as the primary 
molecular target of INH, the first line drug for tuberculosis treatment. But clinical Isolates of M. tuberculosis 
resistant to INH are seen with increasing frequency (1 in 106) compared to other drugs [7]. Over other types of 
resistance, INH resistance was found to be in 10.3 %( new cases) and 27.3 %( treated cases) [8]. The biological 
activity of INH is reduced due to mutation in InhA and Kat G, a catalase/peroxidase enzyme responsible for 
generate bioactive form of INH [9-11]. 
 
Cinnamic acid and its derivatives are well established antimicrobial as well as anti-tubercular agents on and from 
several decades. Many clinical reports further demonstrated the efficacious role of cinnamates in treatment of 
tuberculosis [12-15]. These compounds also show synergistic activity with some first line anti-tubercular agent [16]. 
The precise mode of action of cinnamates as an anti-tubercular agent remains unidentified till date. Even though 
some study demonstrated that Cinnamic acid derivatives can be bound to cofactor binding site of InhA and the 
structural similarity of its enoyl-acyl backbone to the fatty acyl substrate of InhA, make them more reasonable topic 
for further research [17,18,]. Consequently the present study has done to describe the chemical features of existing 
bioactive cinnamic derivatives and to evaluate the key interaction with all feasible binding cavities of InhA (both 
Wild type and mutant protein) by means of computer aided molecular design (CAMD). Both ligand-based drug 
design (LBDD) and structure-based drug design (SBDD) methods were implemented for accomplish the total 
experiment and acquired computational information can reveal  the crucial structural features of cinnamic acid 
derivatives as a potential class of anti-MDR tubercular agent.  
2. Material and Method 
2.1 General methodology 
  
All pharmacophore and 3D QSAR models were generated by PHASE module of Maestro 9.1 software (Schrödinger 
LLC, New York) [19-21]. The protein structures were obtained from RCSB protein data bank (PDB) and docking 
studies were performed using JAGUAR and GLIDE module of MAESTRO 9.1 in extra precision (XP) mode [22]. 
 
2.2 Data set Preparation 
 
For this study, a series of 44 compounds include thioester, amide, hydrazide, triazolophthalazine derivatives of 4-
alkoxy and 4-hydroxy Cinnamic acid with some cyclopropyl derivatives, was collected from literature [25, 26]. The 
reported MIC (minimum inhibitory concentration) value was considered as biological activity property, estimated by 
in vitro assay of M. tuberculosis (H37RV strain).These MIC values were subjected to corresponding logarithmic 
correction using the formula {act= -log (MIC)}[27]. 
The structures were drawn using Chemdraw Ultra 8.0 software [24].The 3D conversion and minimization steps were 
performed using OPLS 2005 Force field [27], with an implicit GB/SA solvent model, implemented in LigPrep 
Module. A maximum of 1,000 conformers were generated for each structure using pre-process minimization of 100 
steps and post-process minimization of 50 steps.  Each minimized conformer was filtered through a relative energy 
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window of 10 kcal mol−1 and a minimum atom deviation of 1.00 Å [19-21]. Then Single-point energy calculation, 
an ab initio quantum chemical method (B3LYP/6-31G**) was conducted in JAGUAR module using Density 
Functional Theory (DFT) for each molecule [28, 29]. An arbitrary adopting method was applied to divide the total 
data set into training set (70% of total molecule) and Test set (remain 30%) for validation purpose. 
 
Table 1. Dataset of Cinnamic acid derivatives with corresponding pIC50 values. 
 
Compound R1 R2 R3 R4 pIC50 
2a Isopentenyl H H N-acetylcysteamine 4.018 
2b Geranyl H H N-acetylcysteamine 5.826 
2c Farnesyl H H N-acetylcysteamine 5.894 
2d methyl H H N-acetylcysteamine 3.647 
2e H H H N-acetylcysteamine 3.624 
2f H OCH3 H N-acetylcysteamine 3.373 
2g H OCH3 OCH3 N-acetylcysteamine 3.415 
3e H H H      Thiophenyl 4.506 
3f H OCH3 H Thiophenyl 4.554 
4a Isopentenyl H H N-acetylethelenediamine 3.701 
4b Geranyl H H N-acetylethelenediamine 6.585 
5a Isopentenyl H H 2-(1H-indol-3-yl)ethanamine 3.774 
5b Geranyl H H 2-(1H-indol-3-yl)ethanamine 4.141 
5d methyl H H 2-(1H-indol-3-yl)ethanamine 2.807 
5f H OCH3 H 2-(1H-indol-3-yl)ethanamine 4.624 
6a Isopentenyl H H 2-aminopyridine 4.285 
6b Geranyl H H 2-aminopyridine 5.576 
6d methyl H H 2-aminopyridine 3.606 
6h methyl OCH3 H 2-aminopyridine 3.357 
10a methyl H H D-cycloserine 3.022 
11a methyl H H INH* 6.523 
11b CF3 H H INH* 5.959 
11c ethyl H H INH* 5.886 
11d CF3CH 2 - H H INH* 5.658 
11e isopentenyl H H INH* 5.638 
11f Geranyl H H INH* 5.721 
12a methyl H H Hydralazine 4.301 
12b CF3- H H Hydralazine 4.678 
12c ethyl H H Hydralazine 4.921 
12d CF3CH 2 - H H Hydralazine 4.699 
12e isopentenyl H H Hydralazine 4.678 
12f Geranyl H H Hydralazine 4.143 
13a methyl H H Triazolophthalazine 4.276 
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13b CF3- H H Triazolophthalazine 3.154 
13c ethyl H H Triazolophthalazine 4.409 
13d CF3CH 2 - H H Triazolophthalazine 3.77 
13e isopentenyl H H Triazolophthalazine 5.854 
13f Geranyl H H triazolophthalazine 4.721 
 
Table 2. Cyclopropyl derivatives. 
 
* INH= Isoniazid, pIC50= Observed biological activity. 
 
2.3 Generation of Pharmacophoric sites and common pharmacophore hypothesis 
 
The structure of compound is defined by a set of points in 3D space, which communicate with different chemical 
features to facilitate non-covalent binding of the compound and its receptor. The six built-in pharmacophore 
features-hydrogen bond acceptor  (A),  hydrogen  bond  donor  (D),  hydrophobic group  (H),  negatively  charged  
group  (N),  positively charged  group  (P)  and  aromatic  ring  (R) were used to create pharmacophoric sites. The 
pattern of pharmacophoric features are specified as SMARTS query [21, 30]. Common pharmacophore features 
were identified from a set of variants — a set of feature types that define a possible pharmacophore, using a tree-
based partitioning algorithm with a maximum tree depth of five with the requirement that all actives must match. 
Scoring of pharmacophore hypothesis with respect to activity of ligand was conducted using default parameters for 
site, vector and volume terms. The activity threshold was set between 5.5 and 4.3 to define active and inactive 
ligands. 
 
2.4 Building 3D QSAR model  
 
An atom-based 3D QSAR model was generated by correlating the observed and estimated activity for training set 
of 31 molecules using Partial least square (PLS) regression analysis with grid spacing of 1.0 Å. The maximum 
number of PLS factor can be taken is N/5, where N is number of training set candidates. The best QSAR model was 
validated by predicting activity of the set of 13 test molecules. 
 
2.5 Validation of QSAR model 
 
An external validation method along with internal model validation techniques has been done simultaneously to 
justify the statistical significance of developed 3D-QSAR model. For external validation, R2pred parameter was 
considered which precisely reflects the degree of correlation between the observed and predicted property data [31]. 
The values of Q2, Q2 (F2) and Pearson –R were also calculated as a parameter for external validation method [32]. 
 
2.6 Macromolecular preparation 
 
The X-ray crystallographic structures of all protein molecules viz. wild type enoyl-acyl carrier protein reductase 
(ENR/InhA) with four more mutated variety ( S94A, I21V, I47T,D148G) of this protein having clinical significance 
,were retrieved from RCSB protein Data bank (http://www.rcsb.org/pdb, PDB ID: 2PR2, 2AQI, 2IE0, 
4DQU,4DT1,1BVR,2NSD ). The best proteins were selected by analyzing all entries with Ramachandran plot [33] 
Compound R1 pIC50 
14a methyl 3.40 
14b CF3- 3.77 
14c ethyl 3.42 
14d CF3CH2  2.88 
14e isopentenyl 4.67 
14f Geranyl 4.55 
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The protein structures co-crystallized with ligands or substrates were subjected for further refinement using 
PrepWizard module of Schrödinger software to add missing hydrogens, assign appropriate bond orders and formal 
charges, treating selenomethionines, di-sulfide bonds etc. Finally, energy minimization step was carried out with 
RMSD (root mean square deviation) value of 0.30 Å and using OPLS_2005 force field [34] 
 
2.7 Molecular Docking 
 
 Receptor-Grid generation of prepared proteins, an important step in GLIDE docking protocol, is performed to 
pre-define the binding site for the ligands. The shape and the properties of the receptor are represented on a grid by 
several different sets of fields that provide progressively more accurate scoring of the ligand poses [35]. 
The docking studies were done for all prepared protein separately using GLIDE 5.5 module [35]. We engaged 
extra precision (XP) mode which uses Monte Carlo based simulated algorithm (MCSA) for minimization. The best 
docking poses with low Glide score and least binding energy was subjected for further investigation [36, 37]. 
3. RESULT AND DISCUSSION 
3.1 Generation of pharmacophore model 
 
Several five-featured common pharmacophore hypotheses with various combinations of sites were generated and 
the best hypotheses were selected on the basis of scoring function and selectivity. All training set compounds were 
aligned on best three selected hypotheses which consist of hydrogen bond acceptor (A), hydrophobic (H),hydrogen 
bond donor and ring feature (R) ,denoted as AADHR, AAAHR and AAADR. Each model was engaged for Partial 
Least Square (PLS) analysis with five PLS factor to avoid over-fitting of the result .The predictive ability of the 
model was re-evaluated by the test set compounds. As internal validation is not sufficient enough to define the 
predictive power of a QSAR model, we considered some external validation statistics (R2Pred and Q2 (F2)) to choose 
best model (AAAHR) [38]. A summary of relevant statistical data of QSAR model is listed in Table-3. Graph of 
observed versus predicted biological activity of training and test set molecules are shown in Fig- 1. 
 
Table 3. Summary of 3D QSAR results with external and internal validation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Scatter plots for observed versus predicted biological activity of (a) training set and (b) test set compounds. 
 
3.2 3D QSAR Analysis 
 
ID SD R-squared F Q2 Pearson-R R2Pred Q2(F2) 
AADHR.11 0.0454 0.9983 2900.1 0.2601 0.5368 0.27 0.73 
AAAHR.218 0.1463 0.9848 324.6 0.8498 0.936 0.85 0.854 
AAADR.166 0.2856 0.9401 81.5 0.7369 0.9109       0.67 0.255 
(a) (b) 
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PHASE 3D QSAR technique gives the advantage of visualizing feature-based counter cubes on favourable and 
unfavourable region in 3D space. The cubes obtained from statistically validated model AAAHR can illustrate the 
features important for interaction between ligands and target enzyme or receptor. In present representation, blue, 
green and cyan cubes indicate favourable region for H-bond acceptor, hydrophobic and electron withdrawing group 
respectively while red cubes express unfavourable region for biological activity. Comparative analysis of physico-
chemical region is done with highest active (4b), lowest active (5d) and a reference molecule (11d) [Fig- 2] 
Fig – 2(c, d) shows the green cubes generated for favourable hydrophobic region near CF3CH2- (R1) and INH 
(R4) group on both side of reference molecule (11d). This clearly indicates that substitution of hydrophobic group in 
these regions may increase biological activity. Therefore ,introduction of  bulky Geranyl, Farnesyl groups in R1 
position drastically increase the activity in highest active compounds like 4b,2b,2c,6b, and negatively regulates the 
activity on 5d,4d,2g,13b,10a molecules which lack off bulky substitutes. This discussion also gives an idea about the 
topology of receptor site. 
Another crucial blue counter map or H-bond donor favourable region is found around Nitrogen atoms of 
hydrazide (-NH-NH-) group (R4 substitution) of reference molecule, which indicates the presence of secondary 
amino group can improve bioactivity [Fig. 2.e]. Therefore, Substitution of N-acetylethelenediamine, N-
acetylcysteamine, pyridyl amides, INH in R4 position immensely increase activity of compounds (4b, 2b, 2c, 6b, 
11b, 11c) and authenticates our observation. Red cubes indicates sterically unfavoured Donor property  between two 
close –NH groups in  11d , which is overcome by  N-acetylethelenediamine substitution in highest active 
compound(4b). 
 
Fig. 2. (a) Alignment of best fit active molecule on AAAHR hypotheses. Red spheres with vector arrow represent the acceptor (A) properties, 
green sphere for hydrophobic (H) and brown ring denotes aromatic ring feature(R).(b-e) cyan, green and blue cubes are favourable regions 
respectively for electron-withdrawing, hydrophobic and H-bond donor features and red cubes denotes unfavourable area for respective features. 
 
3.3 Docking results 
 
The docking simulation was performed using GLIDE (Grid based ligand docking with energetics) program with 
energy calculated ligands. The set of ligands were included with Isoniazid and Isoniazid-NAD adduct for 
comparative binding mode study. 
Pathway analysis and structural studies on  ligand bound protein complex have revealed three putative binding 
clefts of InhA, (i) cofactor NADH binding pocket, (ii) fatty acyl substrate binding site and (iii) the pocket into which 
the isonicotinoyl group of INH-NAD sticks out [39-41]. The molecules were docked into each site also with mutant 
varieties and each docking simulation model was assayed separately [Fig. 5].  
 
3.4 Binding mode analysis 
 
3.4.1 Docking with co-factor binding site of wild-type and mutatated protein 
a b
b
d 
c 
e 
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Co –factor(NADH) binding pocket is also competitively occupied by INH-NAD adduct, a slow and tight 
binder of InhA [34]  .Here we conducted molecular docking with Wt InhA( 2PR2) and  S94A, I21V, I47T,D148G 
(INH resistant) mutated InhA in complex with NADH or INH-NAD. Docking pose of both aforesaid ligands reveal 
that H-bond interaction with residues like Ser 20,Gly14, Gly 96, Lys 165,Ile 21, Val65 ,Asp 64, Ile 194 ,Ser 94, Ala  
198 ,Thr 17 ,Thr 196 and a profound hydrophobic pocket (surrounded by  Phe 41, Ile 122, Leu 63, Val 65 , Ile 95, 
Phe 97, Lys 118, Ile 16 ) provides for binding. Molecules with good binding affinity (5b, 5a, 3f, and 11d) have 
nicely engaged the hydrophobic region and no H-bond interaction with glycin-rich loop make these more feasible 
for INH-resistant strains [42-44]. Oxygen atom of enoyl-acyl back bone of compounds made important H-bond, 
where absent of this property in cyclopropyl derivatives (14a-14f) decrease its bio-activity. 
 
3.4.2 Docking into the binding site of direct InhA inhibitor 
The isonicotinoyl moieties of the INH-NAD and Ethionamide (ETH)-NAD adduct were inserted in a 
hydrophobic pocket formed with a flexible side-chain of residue Phe 149. The cavity was situated  below the fatty 
acyl substrate-binding site and, lined prominently by hydrophobic  residues  of Tyr 158, Phe 149, Met199, Trp 222, 
Leu 218, Met155, Met161, Gly192, and Pro193 [42] [Fig. 4.b]. Study showed that bulky aliphatic substitution, most 
preferably isopentenyl group in R1 position, perfectly occupied the cavity and enhanced the binding affinity 
drastically (e.g. compound 6a, 4a.2a, 12e, 11e, 11f). Along with that, two crucial H-bonds between the O atom of 
enoyl chain of cinnamic acid scaffold with Tyr 158 and co-factor NADH, co-crystallized with enzyme, perfectly 
supports result of 3D QSAR analysis. 
 
3.4.3 Interaction with substrate binding region 
 InhA, a member of FAS II pathway prefers longer chain fatty acyl substrates which is engulfed by 
substrate binding hydrophobic loop (residue 196-219) [45] . Present study reveals that hydrophobic residues like Tyr 
158, Phe 149, Pro 193, Ile 215, Leu 218, Ile 202, Ala 198, Ala 201 and Leu 207 acquire important role in 
interaction. The benzene ring of cinnamates with aliphatic chain substitution played decisive role in hydrophobic 
entrapment.  Compound 5f, 13f, 3f, 4b, 5b, 2b etc were identified on the basis of XP docking score, docking energy 
and 0hydrophobic enclosure reward 
All structure-based docking simulation models show good complementarities with 3D QSAR model. Direct 
inhibitor model is observed as most definitive to QSAR result. 
 
Fig.4. Hydrophobic part in CPK representation of (a) co-factor binding site, (b) direct inhibitor binding cavity and (c) substrate binding site which 
are docked with ligands having highest binding affinity. 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Docking score distribution chart for all three types of docking simulation. 
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4. CONCLUTION 
We have investigated the significances of various structural features of cinnamic acid derivatives as a potential anti-
tubercular agent using the hybrid in silico docking and pharmacophore mapping approaches. Our predicted activity 
data for the cinnamic acid derivatives displays excellent correlations with the experimental activity, confirming the 
accuracies of our simulations. Our docking results demonstrate that the top orders against the InhA enzymes are 
dominated by bulky hydrophobic groups, H-bond acceptors and aromatic ring property, and these features also show 
excellent conformity with ligand-based pharmacophore model. Further exploration on these structural guidelines 
and development of new computational intelligence screening tools using this combined structure-guided model, 
may be helpful to  assay chemical spaces for design of the  novel inhibitors against MDR strains. 
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